Articles related to FDA

Mirvetuximab soravtansine represents a pivotal shift in treating platinum-resistant ovarian cancer, demonstrating not only improved survival outcomes but also a higher response rate compared to standard chemotherapy.

The Supreme Court’s deliberations on the Chevron deference and FDA’s drug approval authority underscore a critical juncture for healthcare delivery and regulatory practices, potentially reshaping physician autonomy and patient care standards.

Explore the latest breakthrough in GAD treatment: MM120 demonstrates remarkable, sustained reduction in anxiety symptoms, offering new hope for patients with severe generalized anxiety disorder.

In oncology, the balance between rapid innovation and patient safety is critical. The recent withdrawal of an accelerated approval cancer drug highlights the need for more stringent evidence and robust trial design to truly benefit patients.

Explore the latest advancement in NSCLC treatment: the FDA-approved amivantamab combo has demonstrated a significant leap in progression-free survival for patients with specific genetic mutations, reshaping the standard of care.

Explore the recent FDA approval of biweekly teclistamab dosing for multiple myeloma, a significant stride in offering personalized treatment schedules that cater to patient and clinician needs.